Global Orphan Diseases Partnering 2010-2016: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2016
No. of pages: 250
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Orphan Diseases Partnering 2010 to 2016 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Orphan Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Orphan Diseases partnering agreement structure

Orphan Diseases partnering contract documents

Top Orphan Diseases deals by value

Most active Orphan Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.

The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Orphan Diseases technologies and products.

Report scope

Global Orphan Diseases Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Orphan Diseases trends and structure of deals entered into by leading companies worldwide.

Global Orphan Diseases Partnering 2010 to 2016 includes:

Trends in Orphan Diseases dealmaking in the biopharma industry since 2010

Analysis of Orphan Diseases deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Orphan Diseases deal contract documents

Comprehensive access to over 3500 Orphan Diseases deal records

The leading Orphan Diseases deals by value since 2010

Most active Orphan Diseases dealmakers since 2010

In Global Orphan Diseases Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Orphan Diseases Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 100 orphan diseases deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Orphan Diseases Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Orphan Diseases deal trends since 2010

Access Orphan Diseases deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Orphan Diseases partner companies

Comprehensive access to over 750 links to actual Orphan Diseases deals entered into by the world's biopharma companies

Indepth review of Orphan Diseases deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Orphan Diseases opportunities

Uncover companies actively partnering Orphan Diseases opportunities

Global Orphan Diseases Partnering 2010-2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Orphan Diseases dealmaking
2.1. Introduction
2.2. Orphan Diseases partnering over the years
2.3. Orphan Diseases partnering by deal type
2.4. Orphan Diseases partnering by industry sector
2.5. Orphan Diseases partnering by stage of development
2.6. Orphan Diseases partnering by technology type
2.7. Orphan Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Orphan Diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for Orphan Diseases partnering
3.3. Orphan Diseases partnering headline values
3.4. Orphan Diseases deal upfront payments
3.5. Orphan Diseases deal milestone payments
3.6. Orphan Diseases royalty rates

Chapter 4 - Leading Orphan Diseases deals and dealmakers
4.1. Introduction
4.2. Most active in Orphan Diseases partnering
4.3. List of most active dealmakers in Orphan Diseases
4.4. Top Orphan Diseases deals by value

Chapter 5 - Orphan Diseases contract document directory
5.1. Introduction
5.2. Orphan Diseases partnering deals where contract document available

Chapter 6 - Orphan Diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Orphan Diseases therapeutic target

Appendices
Appendix 1 - Directory of Orphan Diseases deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Orphan Diseases deals by deal type 2010 to 2016
Appendix 3 - Directory of Orphan Diseases deals by stage of development 2010 to 2016
Appendix 4 - Directory of Orphan Diseases deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Orphan Diseases partnering since 2010
Figure 2: Orphan Diseases partnering by deal type since 2010
Figure 3: Orphan Diseases partnering by industry sector since 2010
Figure 4: Orphan Diseases partnering by stage of development since 2010
Figure 5: Orphan Diseases partnering by technology type since 2010
Figure 6: Orphan Diseases partnering by indication since 2010
Figure 7: Orphan Diseases deals with a headline value
Figure 8: Orphan Diseases deals with upfront payment values
Figure 9: Orphan Diseases deals with milestone payment
Figure 10: Orphan Diseases deals with royalty rates
Figure 11: Active Orphan Diseases dealmaking activity- 2010 to 2016
Figure 12: Top Orphan Diseases deals by value since 2010
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Anti Peptic Ulcer Drugs Markets in China
    Published: 15-Jan-2017        Price: US 4000 Onwards        Pages: 211
    China's demand for Anti Peptic Ulcer Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity,......
  • Anti Peptic Ulcer Drugs Companies in China
    Published: 15-Jan-2017        Price: US 1800 Onwards        Pages: 54
    This study focuses on China's Anti Peptic Ulcer Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumpt......
  • Anti Peptic Ulcer Drugs Industry Forecasts - China Focus
    Published: 15-Jan-2017        Price: US 1800 Onwards        Pages: 107
    This study focuses on China's Anti Peptic Ulcer Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and servi......
  • United States Generic Drugs Market Report 2017
    Published: 13-Jan-2017        Price: US 3800 Onwards        Pages: 108
    Notes: Sales, means the sales volume of Generic Drugs Revenue, means the sales value of Generic Drugs This report studies sales (consumption) of Generic Drugs in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Teva Pharma. - Novartis company - Mylan - Allergan - Hospira - Dr. Reddy's Lab. - Stada - Greenstone - Par Pharma - S......
  • Global Capecitabine Fumarate Market Professional Survey Report 2017
    Published: 13-Jan-2017        Price: US 3500 Onwards        Pages: 121
    Notes: Production, means the output of Capecitabine Fumarate Revenue, means the sales value of Capecitabine Fumarate This report studies Capecitabine Fumarate in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, rev......
  • Global Lincomycin HCL Sales Market Report 2017
    Published: 13-Jan-2017        Price: US 4000 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Lincomycin HCL Revenue, means the sales value of Lincomycin HCL This report studies sales (consumption) of Lincomycin HCL in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Pfizer - Nanyang PuKang - Henan TOPFOND - Anhui Wanbei - NCPC......
  • Global Minocycline Hydrochloride Sales Market Report 2017
    Published: 13-Jan-2017        Price: US 4000 Onwards        Pages: 108
    Notes: Sales, means the sales volume of Minocycline Hydrochloride Revenue, means the sales value of Minocycline Hydrochloride This report studies sales (consumption) of Minocycline Hydrochloride in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Euticals - Hovione - Atral Cipan - T......
  • Global Solid Organ Transplant Immunosuppressant Market Research Report 2017
    Published: 10-Jan-2017        Price: US 2900 Onwards        Pages: 124
    Notes: Production, means the output of Solid Organ Transplant Immunosuppressant Revenue, means the sales value of Solid Organ Transplant Immunosuppressant This report studies Solid Organ Transplant Immunosuppressant in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Astellas Phar......
  • United States Nicotine Gum Market Report 2017
    Published: 10-Jan-2017        Price: US 3800 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Nicotine Gum Revenue, means the sales value of Nicotine Gum This report studies sales (consumption) of Nicotine Gum in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Novartis - Perrigo Company - Pfizer - Fertin Pharma - GlaxoSmithKline - Revolymer - Johnson & Johnson - Cambrex Corporation - R......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs